Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Quoin Pharmaceuticals ( (QNRX) ) has shared an update.
Quoin Pharmaceuticals Ltd. announced the mutual separation with its former Chief Financial Officer, Gordon Dunn, effective August 15, 2025. The company finalized a Separation Agreement with Mr. Dunn, which includes a payment plan, a bonus for the 2024 financial year, and an extension of the period to exercise stock options, reflecting a structured transition in its financial leadership.
The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.
Spark’s Take on QNRX Stock
According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.
Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.
To see Spark’s full report on QNRX stock, click here.
More about Quoin Pharmaceuticals
Average Trading Volume: 7,053
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.34M
See more insights into QNRX stock on TipRanks’ Stock Analysis page.